S&P 500   4,287.15 (+1.57%)
DOW   33,786.24 (+2.19%)
QQQ   354.86 (+0.81%)
AAPL   180.61 (+0.29%)
MSFT   335.66 (+0.93%)
META   273.41 (+0.29%)
GOOGL   124.92 (+0.97%)
AMZN   124.77 (+1.63%)
TSLA   216.12 (+4.14%)
NVDA   392.91 (-1.20%)
NIO   7.64 (+1.33%)
BABA   84.81 (+2.18%)
AMD   118.31 (-0.97%)
T   15.14 (-4.24%)
F   12.42 (+2.56%)
MU   69.30 (+0.30%)
CGC   0.82 (-1.23%)
GE   106.47 (+1.72%)
DIS   91.06 (+2.79%)
AMC   4.56 (+0.22%)
PFE   38.48 (+1.21%)
PYPL   63.96 (+1.44%)
NFLX   402.38 (-0.19%)
S&P 500   4,287.15 (+1.57%)
DOW   33,786.24 (+2.19%)
QQQ   354.86 (+0.81%)
AAPL   180.61 (+0.29%)
MSFT   335.66 (+0.93%)
META   273.41 (+0.29%)
GOOGL   124.92 (+0.97%)
AMZN   124.77 (+1.63%)
TSLA   216.12 (+4.14%)
NVDA   392.91 (-1.20%)
NIO   7.64 (+1.33%)
BABA   84.81 (+2.18%)
AMD   118.31 (-0.97%)
T   15.14 (-4.24%)
F   12.42 (+2.56%)
MU   69.30 (+0.30%)
CGC   0.82 (-1.23%)
GE   106.47 (+1.72%)
DIS   91.06 (+2.79%)
AMC   4.56 (+0.22%)
PFE   38.48 (+1.21%)
PYPL   63.96 (+1.44%)
NFLX   402.38 (-0.19%)
S&P 500   4,287.15 (+1.57%)
DOW   33,786.24 (+2.19%)
QQQ   354.86 (+0.81%)
AAPL   180.61 (+0.29%)
MSFT   335.66 (+0.93%)
META   273.41 (+0.29%)
GOOGL   124.92 (+0.97%)
AMZN   124.77 (+1.63%)
TSLA   216.12 (+4.14%)
NVDA   392.91 (-1.20%)
NIO   7.64 (+1.33%)
BABA   84.81 (+2.18%)
AMD   118.31 (-0.97%)
T   15.14 (-4.24%)
F   12.42 (+2.56%)
MU   69.30 (+0.30%)
CGC   0.82 (-1.23%)
GE   106.47 (+1.72%)
DIS   91.06 (+2.79%)
AMC   4.56 (+0.22%)
PFE   38.48 (+1.21%)
PYPL   63.96 (+1.44%)
NFLX   402.38 (-0.19%)
S&P 500   4,287.15 (+1.57%)
DOW   33,786.24 (+2.19%)
QQQ   354.86 (+0.81%)
AAPL   180.61 (+0.29%)
MSFT   335.66 (+0.93%)
META   273.41 (+0.29%)
GOOGL   124.92 (+0.97%)
AMZN   124.77 (+1.63%)
TSLA   216.12 (+4.14%)
NVDA   392.91 (-1.20%)
NIO   7.64 (+1.33%)
BABA   84.81 (+2.18%)
AMD   118.31 (-0.97%)
T   15.14 (-4.24%)
F   12.42 (+2.56%)
MU   69.30 (+0.30%)
CGC   0.82 (-1.23%)
GE   106.47 (+1.72%)
DIS   91.06 (+2.79%)
AMC   4.56 (+0.22%)
PFE   38.48 (+1.21%)
PYPL   63.96 (+1.44%)
NFLX   402.38 (-0.19%)
NASDAQ:PRTG

Portage Biotech (PRTG) Stock Forecast, Price & News

$3.57
-0.09 (-2.46%)
(As of 02:33 PM ET)
Compare
Today's Range
$3.53
$3.79
50-Day Range
$2.68
$3.66
52-Week Range
$2.34
$11.99
Volume
18,883 shs
Average Volume
30,104 shs
Market Capitalization
$60.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

Portage Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
426.3% Upside
$19.00 Price Target
Short Interest
Healthy
0.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.95) to ($1.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

855th out of 1,980 stocks

Crude Petroleum & Natural Gas Industry

129th out of 160 stocks


PRTG stock logo

About Portage Biotech (NASDAQ:PRTG) Stock

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors; TT-4, an adenosine receptor type 2B (A2B) inhibitor to treat solid tumors; TT-53, an A2A/A2B inhibitor to treat solid tumors; TT-3, an A2B inhibitor to treat colorectal and gastrointestinal cancers; and NT230-6 that is in Phase I/II clinical trials for the treatment of tumors. It also provides Nanolipogel (NLG) co-formulation platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products; and STING agonist platform, a proprietary immune priming and boosting technology, offers various ways to target immune stimulation towards the cancer, as well as to co-deliver various signals in a single product. The company is based in Tortola, British Virgin Islands.

Receive PRTG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Portage Biotech and its competitors with MarketBeat's FREE daily newsletter.

PRTG Stock News Headlines

The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
Portage Central High School
Portage High School
Track Covid-19 in Portage County, Wisconsin
Portage Biotech Stock (NASDAQ:PRTG), Dividends
The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
Portage Biotech reports FY results
PRTG Portage Biotech Inc.
7PRTG : HC Wainwright & Co. Maintains Buy...
Portage Biotech GAAP EPS of -$0.13
Portage Biotech: Q1 Earnings Insights
See More Headlines

PRTG Price History

PRTG Company Calendar

Last Earnings
11/22/2021
Today
6/02/2023
Next Earnings (Estimated)
8/07/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Crude petroleum & natural gas
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRTG
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+419.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-16,870,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$12.40 per share

Miscellaneous

Free Float
9,816,000
Market Cap
$62.00 million
Optionable
Not Optionable
Beta
1.30

Key Executives

  • Dr. Ian B. Walters M.B.A. (Age 54)
    M.D., CEO & Chairman of Board
    Comp: $848.15k
  • Mr. Allan J. Lee Shaw CPA (Age 58)
    Chief Financial Officer
    Comp: $430.95k
  • Mr. Steven Innaimo
    VP of Project Management & Operations
  • Dr. Robert A. Kramer Ph.D.
    Chief Scientific Officer
  • Mr. Brian Wiley (Age 54)
    Chief Bus. Officer
    Comp: $252.17k
  • Mr. Joseph Ciavarella
    Chief Accounting Officer













PRTG Stock - Frequently Asked Questions

Should I buy or sell Portage Biotech stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Portage Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRTG shares.
View PRTG analyst ratings
or view top-rated stocks.

What is Portage Biotech's stock price forecast for 2023?

3 Wall Street analysts have issued twelve-month target prices for Portage Biotech's shares. Their PRTG share price forecasts range from $18.00 to $21.00. On average, they predict the company's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 419.1% from the stock's current price.
View analysts price targets for PRTG
or view top-rated stocks among Wall Street analysts.

How have PRTG shares performed in 2023?

Portage Biotech's stock was trading at $5.2891 at the beginning of the year. Since then, PRTG stock has decreased by 30.8% and is now trading at $3.66.
View the best growth stocks for 2023 here
.

When is Portage Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023.
View our PRTG earnings forecast
.

How were Portage Biotech's earnings last quarter?

Portage Biotech Inc. (NASDAQ:PRTG) issued its earnings results on Monday, November, 22nd. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.03.

What is Portage Biotech's stock symbol?

Portage Biotech trades on the NASDAQ under the ticker symbol "PRTG."

Who are Portage Biotech's major shareholders?

Portage Biotech's stock is owned by many different retail and institutional investors. Top institutional shareholders include MAI Capital Management (0.46%) and Simplex Trading LLC (0.00%).

How do I buy shares of Portage Biotech?

Shares of PRTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Portage Biotech's stock price today?

One share of PRTG stock can currently be purchased for approximately $3.66.

How much money does Portage Biotech make?

Portage Biotech (NASDAQ:PRTG) has a market capitalization of $62.00 million. The company earns $-16,870,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.

How can I contact Portage Biotech?

Portage Biotech's mailing address is Craigmuir Chambers Road Town, Tortola D8, VG1110. The official website for the company is www.portagebiotech.com. The company can be reached via phone at 416-929-1806.

This page (NASDAQ:PRTG) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -